Tuesday, May 4, 2010

GLENMARK PHARMA update

Videos of our seminars http://www.youtube.com/user/akprabhakar  


Glenmark Pharmaceuticals S.A (GPSA), a wholly owned subsidiary of Glenmark Pharmaceuticals (GPL) has announced that it has entered into an agreement with Sanofi-Aventis to grant Sanofi-Aventis a license for the development and commercialization of novel agents to treat chronic pain. Those agents are vanilloid receptor (TRPV3) antagonist molecules, including a first-in-class clinical compound, GRC 15300. GRC 15300 is currently in Phase I clinical development as a potential next-generation treatment for various pain conditions, including diabetic neuropathic pain and osteoarthritic pain.
Under the terms of the agreement, Glenmark will receive an upfront payment of $20 million, as well as development, regulatory and commercial milestone payments, it said in a statement. The total licensing payments could reach $325 million, the company added.

 
The stock hit a high of Rs 303.80, which is also its 52-week high after a Gap-up opening and Rs.272-276 Gap is still pending and sustaining higher levels the stock can soon reach our FABULOUS-15 Target of Rs.350

Everest Kanto Cylinder jumped 9% on reports the company expects its operations in China to bring in significant revenue http://www.capitalmarket.com/if.asp?L=hotpursuit&M=cmedit/story2-0.asp?sno=391299  


http://www.telegraphindia.com/1100504/jsp/business/story_12409157.jsp  


http://www.thehindubusinessline.com/2010/05/04/stories/2010050450650200.htm  


http://www.business-standard.com/india/news/glenmark-sanofi-in-outlicensing-deal/393730/  Glenmark, Sanofi in out licensing deal Deal potential of Rs 1,447 crore for development of molecule to treat chronic pain.


Latest Update-----
Par Pharmaceutical has entered into an exclusive licencing agreement with Glenmark Generics for Zetia, reports CNBC-TV18. Under the terms of the licensing and supply agreement, the US-based specialty pharmaceutical company has made a payment to Glenmark for exclusive rights to market, sell and distribute ezetimibe 10 mg tablets, the generic version of Merck & Co's Zetia in the US http://www.moneycontrol.com/news/business/par-pharma-glenmark-genericslicencing-pact-for-zetia_455543.html

Beijing Airport Word's Largest Airport